Jenalyn L. Yumol, Sylvie Binda, Varuni Nagulesapillai, Renu Bhardwaj, Wendy E. Ward
{"title":"使用益生菌补充剂支持绝经后妇女骨骼健康：一项随机、双盲、平行、安慰剂对照的多中心研究","authors":"Jenalyn L. Yumol, Sylvie Binda, Varuni Nagulesapillai, Renu Bhardwaj, Wendy E. Ward","doi":"10.1007/s11657-025-01589-2","DOIUrl":null,"url":null,"abstract":"<div><h3>\n <i>Summary</i>\n </h3><p>Studies using rodent models have demonstrated the ability for probiotics to attenuate estrogen-related bone loss, but findings in humans are limited. Postmenopausal women consuming a novel combination of bacteria strains as a probiotic supplement demonstrated no changes in bone health outcomes.</p><h3>Purpose</h3><p>This study determined if a probiotic supplement could attenuate the loss of femoral neck bone mineral density (BMD) and assessed its effect on fracture risk and markers of bone cell activity.</p><h3>Methods</h3><p>Seventy-two postmenopausal women (40–59 years) were randomized to a daily probiotic supplement or placebo for 48 weeks. Femoral neck BMD was assessed at weeks 0 and 48 using DXA along with fracture risk using the FRAX® assessment tool. Serum procollagen type 1 N-terminal propeptide (P1NP), bone-specific alkaline phosphatase (BALP), cross-linked C-telopeptide of type I collagen (CTx), and osteocalcin (OC) were analyzed at weeks 0, 12, 24, and 48.</p><h3>Results</h3><p>There was no significant time by treatment interaction (<i>p</i> > 0.05) for femoral neck BMD or fracture risk. Independent of treatment, femoral neck BMD decreased (<i>p</i> = 0.034), while risk of hip (<i>p</i> = 0.003) and major osteoporotic fracture (<i>p</i> = 0.044) increased. There was no mean difference in bone marker levels between groups from baseline to endpoint. These findings align with the lack of difference in BMD and fracture risk at the end of study.</p><h3>Conclusion</h3><p>Probiotics did not alter BMD or fracture risk, as supported by bone cellular activity that was similar to the placebo group by the end of study.</p></div>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296836/pdf/","citationCount":"0","resultStr":"{\"title\":\"Using probiotic supplementation to support bone health in postmenopausal women: a randomized, double-blind, parallel, placebo-controlled, multi-center study\",\"authors\":\"Jenalyn L. Yumol, Sylvie Binda, Varuni Nagulesapillai, Renu Bhardwaj, Wendy E. Ward\",\"doi\":\"10.1007/s11657-025-01589-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>\\n <i>Summary</i>\\n </h3><p>Studies using rodent models have demonstrated the ability for probiotics to attenuate estrogen-related bone loss, but findings in humans are limited. Postmenopausal women consuming a novel combination of bacteria strains as a probiotic supplement demonstrated no changes in bone health outcomes.</p><h3>Purpose</h3><p>This study determined if a probiotic supplement could attenuate the loss of femoral neck bone mineral density (BMD) and assessed its effect on fracture risk and markers of bone cell activity.</p><h3>Methods</h3><p>Seventy-two postmenopausal women (40–59 years) were randomized to a daily probiotic supplement or placebo for 48 weeks. Femoral neck BMD was assessed at weeks 0 and 48 using DXA along with fracture risk using the FRAX® assessment tool. Serum procollagen type 1 N-terminal propeptide (P1NP), bone-specific alkaline phosphatase (BALP), cross-linked C-telopeptide of type I collagen (CTx), and osteocalcin (OC) were analyzed at weeks 0, 12, 24, and 48.</p><h3>Results</h3><p>There was no significant time by treatment interaction (<i>p</i> > 0.05) for femoral neck BMD or fracture risk. Independent of treatment, femoral neck BMD decreased (<i>p</i> = 0.034), while risk of hip (<i>p</i> = 0.003) and major osteoporotic fracture (<i>p</i> = 0.044) increased. There was no mean difference in bone marker levels between groups from baseline to endpoint. These findings align with the lack of difference in BMD and fracture risk at the end of study.</p><h3>Conclusion</h3><p>Probiotics did not alter BMD or fracture risk, as supported by bone cellular activity that was similar to the placebo group by the end of study.</p></div>\",\"PeriodicalId\":8283,\"journal\":{\"name\":\"Archives of Osteoporosis\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-07-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296836/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Osteoporosis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s11657-025-01589-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Osteoporosis","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s11657-025-01589-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Using probiotic supplementation to support bone health in postmenopausal women: a randomized, double-blind, parallel, placebo-controlled, multi-center study
Summary
Studies using rodent models have demonstrated the ability for probiotics to attenuate estrogen-related bone loss, but findings in humans are limited. Postmenopausal women consuming a novel combination of bacteria strains as a probiotic supplement demonstrated no changes in bone health outcomes.
Purpose
This study determined if a probiotic supplement could attenuate the loss of femoral neck bone mineral density (BMD) and assessed its effect on fracture risk and markers of bone cell activity.
Methods
Seventy-two postmenopausal women (40–59 years) were randomized to a daily probiotic supplement or placebo for 48 weeks. Femoral neck BMD was assessed at weeks 0 and 48 using DXA along with fracture risk using the FRAX® assessment tool. Serum procollagen type 1 N-terminal propeptide (P1NP), bone-specific alkaline phosphatase (BALP), cross-linked C-telopeptide of type I collagen (CTx), and osteocalcin (OC) were analyzed at weeks 0, 12, 24, and 48.
Results
There was no significant time by treatment interaction (p > 0.05) for femoral neck BMD or fracture risk. Independent of treatment, femoral neck BMD decreased (p = 0.034), while risk of hip (p = 0.003) and major osteoporotic fracture (p = 0.044) increased. There was no mean difference in bone marker levels between groups from baseline to endpoint. These findings align with the lack of difference in BMD and fracture risk at the end of study.
Conclusion
Probiotics did not alter BMD or fracture risk, as supported by bone cellular activity that was similar to the placebo group by the end of study.
期刊介绍：
Archives of Osteoporosis is an international multidisciplinary journal which is a joint initiative of the International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA. The journal will highlight the specificities of different regions around the world concerning epidemiology, reference values for bone density and bone metabolism, as well as clinical aspects of osteoporosis and other bone diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
